Karyopharm Therapeutics Azioni (NASDAQ: KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) Azioni, Quote.MetaTitle.unusual-options

Karyopharm Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics Inc

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

aTyr Pharma

Biomea Fusion

BeyondSpring

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Clene

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Fortress Biotech

InflaRx

Immunic

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Macrogenics

Metagenomi

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

AVITA Medical

Repare Therapeutics

Sutro Biopharma

Tevogen Bio Holdings

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

XBiotech

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

Karyopharm Therapeutics (KPTI) Previsione

Notizie

Utili

Quote.Nav.option-chain

Guidance

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Comments

Karyopharm Therapeutics Opzioni Inusuali

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO